Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer tr

[News]

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

More... (http://www.news-medical.net/news/20110224/Onyx-Bayer-initiate-patient-enrollment-in-Nexavar-Phase-3-trial-for-breast-cancer-treatment.aspx)